The Australian Metabolic Disorders Therapeutics market size stood at around USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.
The metabolic disorder is increasingly common, both in Australia and overseas. The Australian Diabetes, Obesity and Lifestyle study in 2000, found that 19% of Australians aged 25 years and over met the criteria for a diagnosis of metabolic disorder. The follow-up study in 2004–05, found the annual incidence of the metabolic disorder to be 3%. In 2006 Bettering the Evaluation and Care of Health (BEACH) study found that while 43.7% of patients had central obesity, 15.6% had metabolic disorders. Metabolism is the process through which the body generates energy from food. Food comprises biomolecules, including carbohydrates, proteins, and fats. Chemicals in the digestive system are used to break the food into sugars and acids. Metabolic disorders disrupt the normal function of metabolic processes and lead to excess or lack of essential components that are needed to stay healthy. These disorders are either inherited or acquired during the lifetime of an individual.
Increasing demand for one-time therapies for metabolic disorders and the rising prevalence of lifestyle diseases are the key factors that are expected to boost the growth of this market. Various governments and healthcare associations around the world have estimated that more than half a billion individuals are to be affected by obesity and diabetes by 2040. Also, rising incidences of inherited metabolic diseases due to changing lifestyles are likely to propel the market growth. Other factors that are propelling the market growth are the rapidly aging population, sedentary lifestyles, and increasing cases of smoking and other metabolic pathway restricting practices. The latest data from the National Drug Strategy Household Survey (NDSHS) estimated that 11.6% of adults smoked daily in 2019. The National Health Survey 2014-15 indicates that nearly 30% of Australian adults engaged in low levels of physical activity (less than 150 minutes in the last week) while 14.8% were inactive (no exercise in the last week). Similar proportions of males (15.2%) and females were considered inactive (14.4%).
Major Metabolic Disorders
The major disorders include diabetes, lysosomal disorders, hypercholesterolemia, obesity, and inherited metabolic disorders. These diseases are mostly inherited from the older generation through a faulty gene and some show immediate effects like the lysosomal disorders, while some show up later due to aging.
Diabetes was estimated to be the largest segment due to the wide usage of metabolic disease therapies in anti-diabetic drugs and injections to control blood sugar levels. In diabetes, constant ingestion of metabolic regulators is essential. This factor makes it the largest revenue-generating segment. However, the obesity segment is expected to witness the fastest growth over the forecast period due to increasing lifestyle changes and unhealthy eating habits. In 2017–18, an estimated 2 in 3 (67%) Australians aged 18 and over were overweight or obese.